Literature DB >> 19929435

Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta.

Frank Rauch1, Liljana Lalic, Peter Roughley, Francis H Glorieux.   

Abstract

Osteogenesis imperfecta (OI) is a heritable bone fragility disorder that in the majority of cases is caused by mutations in COL1A1 or COL1A2, the genes that encode the two collagen type I alpha chains, alpha1(I) and alpha2(I). In this study, we examined the relationship between collagen type I mutations and bone densitometric and histomorphometric findings in pediatric OI patients who had not received bisphosphonate treatment. Lumbar spine areal bone mineral density (LS aBMD) was measured in 192 patients (99 girls, 93 boys; age range 3 weeks to 16.9 years) who had either COL1A1 mutations leading to haploinsufficiency (n = 52) or mutations that lead to the substitution of glycine by another amino acid in the triple-helical domain of either the alpha1(I) (n = 58) or the alpha2(I) chain (n = 82). Compared with patients with helical mutations, patients with COL1A1 haploinsufficiency on average were taller and heavier and had higher LS aBMD. After adjustment for age, sex, and height Z-scores, the mean LS aBMD Z-scores were -4.0 for the haploinsufficiency group and -4.7 for both helical mutation groups. In the whole patient population, the average LS aBMD Z-score was higher by 0.6 (95% confidence interval 0.2-1.0) in girls than in boys. Iliac bone histomorphometry (in a subgroup of 96 patients) showed that outer bone size (core width) and trabecular bone volume were similar between genotypic groups, but cortical width was 49% higher in the haploinsufficiency group compared with patients with helical mutations in alpha2(I). Bone turnover parameters were lower in the haploinsufficiency group than in patients with helical mutations. In the group of patients with helical mutations, neither the type of alpha chain affected, nor the type of amino acid substituting for glycine, nor the position of the mutation in the alpha chain had a detectable relationship with LS aBMD or histomorphometric results. Thus patients with haploinsufficiency mutations had a milder skeletal phenotype than patients with mutations affecting glycine residues, but there was no clear genotype-phenotype correlation among patients with helical glycine mutations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19929435     DOI: 10.1359/jbmr.091109

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  45 in total

1.  Clinical and genetic analysis in 185 Chinese probands of osteogenesis imperfecta.

Authors:  Lei Xi; Hao Zhang; Zhen-Lin Zhang
Journal:  J Bone Miner Metab       Date:  2020-10-17       Impact factor: 2.626

2.  Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.

Authors:  L A Bradbury; S Barlow; F Geoghegan; R A Hannon; S L Stuckey; J A H Wass; R G G Russell; M A Brown; E L Duncan
Journal:  Osteoporos Int       Date:  2011-07-08       Impact factor: 4.507

Review 3.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

Review 4.  Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.

Authors:  P Trejo; F Rauch
Journal:  Osteoporos Int       Date:  2016-08-05       Impact factor: 4.507

5.  Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta.

Authors:  Taichi Kitaoka; Noriyuki Namba; Kohji Miura; Takuo Kubota; Yasuhisa Ohata; Makoto Fujiwara; Haruhiko Hirai; Takehisa Yamamoto; Keiichi Ozono
Journal:  J Bone Miner Metab       Date:  2011-02-23       Impact factor: 2.626

6.  The identification of novel mutations in COL1A1, COL1A2, and LEPRE1 genes in Chinese patients with osteogenesis imperfecta.

Authors:  Zhen-Lin Zhang; Hao Zhang; Yao-hua Ke; Hua Yue; Wen-Jin Xiao; Jin-Bo Yu; Jie-Mei Gu; Wei-Wei Hu; Chun Wang; Jin-Wei He; Wen-Zhen Fu
Journal:  J Bone Miner Metab       Date:  2011-06-14       Impact factor: 2.626

7.  Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta.

Authors:  Junko Kanno; Akiko Saito-Hakoda; Shigeo Kure; Ikuma Fujiwara
Journal:  J Bone Miner Metab       Date:  2017-05-20       Impact factor: 2.626

8.  Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing.

Authors:  Y Liu; D Ma; F Lv; X Xu; J Wang; W Xia; Y Jiang; O Wang; X Xing; W Yu; J Wang; J Sun; L Song; Y Zhu; H Yang; J Wang; M Li
Journal:  Osteoporos Int       Date:  2017-07-19       Impact factor: 4.507

Review 9.  Diagnosis and treatment of osteopenic fractures in children.

Authors:  Charles T Mehlman; Marcia A Shepherd; Carie S Norris; Jessica B McCourt
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

10.  A scoring system for the assessment of clinical severity in osteogenesis imperfecta.

Authors:  Mona S Aglan; Laila Hosny; Rasha El-Houssini; Sawsan Abdelhadi; Fadia Salem; Rokia A S Elbanna; Seham A Awad; Moushira E Zaki; Samia A Temtamy
Journal:  J Child Orthop       Date:  2012-02-08       Impact factor: 1.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.